Radiation-associated liver injury.

[1]  G. Lockwood,et al.  Phase I study of individualized stereotactic body radiotherapy of liver metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[3]  R. Sweeney,et al.  Image-guided radiotherapy for liver cancer using respiratory-correlated computed tomography and cone-beam computed tomography. , 2008, International journal of radiation oncology, biology, physics.

[4]  Lech Papiez,et al.  Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[5]  B. Erickson,et al.  Estimate of radiobiologic parameters from clinical data for biologically based treatment planning for liver irradiation. , 2008, International journal of radiation oncology, biology, physics.

[6]  Maria Hawkins,et al.  Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Chang-Min Kim,et al.  Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma. , 2007, International journal of radiation oncology, biology, physics.

[8]  T. Hashimoto,et al.  Proton Beam Therapy for Hepatocellular Carcinoma Patients with Severe Cirrhosis , 2006, Strahlentherapie und Onkologie.

[9]  Hai-jie Lu,et al.  Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. , 2006, International journal of radiation oncology, biology, physics.

[10]  Xiao-dong Zhu,et al.  Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma. , 2006, International journal of radiation oncology, biology, physics.

[11]  T. Kinoshitá,et al.  Extrahepatic portal vein occlusion without recurrence after pancreaticoduodenectomy and intraoperative radiation therapy. , 2006, International journal of radiation oncology, biology, physics.

[12]  M. McCarter,et al.  Interim analysis of a prospective phase I/II trial of SBRT for liver metastases , 2006, Acta oncologica.

[13]  J. Petersen,et al.  Phase II study on stereotactic body radiotherapy of colorectal metastases , 2006, Acta oncologica.

[14]  Peter C Levendag,et al.  Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study , 2006, Acta oncologica.

[15]  R. T. Ten Haken,et al.  Partial volume tolerance of the liver to radiation. , 2005, Seminars in radiation oncology.

[16]  Robert D Timmerman,et al.  A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. , 2005, International journal of radiation oncology, biology, physics.

[17]  Hsiao-Wen Chung,et al.  Inclusion of biological factors in parallel-architecture normal-tissue complication probability model for radiation-induced liver disease. , 2005, International journal of radiation oncology, biology, physics.

[18]  G. Lockwood,et al.  Use of principal component analysis to evaluate the partial organ tolerance of normal tissues to radiation. , 2005, International journal of radiation oncology, biology, physics.

[19]  J. Sung,et al.  Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. , 2004, International journal of radiation oncology, biology, physics.

[20]  Li Liu,et al.  Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. , 2004, World journal of gastroenterology.

[21]  Randall K Ten Haken,et al.  Alterations in normal liver doses due to organ motion. , 2003, International journal of radiation oncology, biology, physics.

[22]  G. van Kaick,et al.  Assessment of focal liver reaction by multiphasic CT after stereotactic single-dose radiotherapy of liver tumors. , 2003, International journal of radiation oncology, biology, physics.

[23]  K. Sugimura,et al.  Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. , 2003, International journal of radiation oncology, biology, physics.

[24]  D L McShan,et al.  Inclusion of organ deformation in dose calculations. , 2003, Medical physics.

[25]  J. Seong,et al.  Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. , 2003, International journal of radiation oncology, biology, physics.

[26]  B. Nordlinger,et al.  Colorectal metastasis (liver and lung). , 2002, The Surgical clinics of North America.

[27]  Daniel Normolle,et al.  Analysis of radiation-induced liver disease using the Lyman NTCP model. , 2002, International journal of radiation oncology, biology, physics.

[28]  S. H. Cheng,et al.  Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication. , 2001, International journal of radiation oncology, biology, physics.

[29]  R. Abrams,et al.  Influence of prognostic groupings and treatment results in the management of unresectable hepatoma: experience with Cisplatinum-based chemoradiotherapy in 76 patients. , 1997, International journal of radiation oncology, biology, physics.

[30]  I. Francis,et al.  High-dose localized radiation therapy for treatment of hepatic malignant tumors: CT findings and their relation to radiation hepatitis. , 1995, AJR. American journal of roentgenology.

[31]  M. Anscher,et al.  Hepatic toxicity resulting from cancer treatment. , 1995, International journal of radiation oncology, biology, physics.

[32]  M. Goitein,et al.  Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.

[33]  M. Anscher,et al.  Transforming growth factor-beta 1 expression in irradiated liver. , 1990, Radiation research.

[34]  K. Russell,et al.  Accelerated fractionation radiation therapy for liver metastases: selection of an optimal patient population for the evaluation of late hepatic injury in RTOG studies. , 1990, International journal of radiation oncology, biology, physics.

[35]  Robert J. Yaes,et al.  Local stem cell depletion model for radiation myelitis , 1988 .

[36]  Tae Hyun Kim,et al.  Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. , 2007, International journal of radiation oncology, biology, physics.

[37]  Shinichi Shimizu,et al.  Intrafractional tumor motion: lung and liver. , 2004, Seminars in radiation oncology.

[38]  R K Ten Haken,et al.  The reproducibility of organ position using active breathing control (ABC) during liver radiotherapy. , 2001, International journal of radiation oncology, biology, physics.

[39]  G J Kutcher,et al.  Analysis of clinical complication data for radiation hepatitis using a parallel architecture model. , 1995, International journal of radiation oncology, biology, physics.

[40]  M. Rotman,et al.  Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol. , 1993, International journal of radiation oncology, biology, physics.